Paying users zone. Data is covered by .

  • Get to Amgen Inc. for $17.99, or

  • get to whole website for at least 3 months from $49.99.

 

$17.99


Free Cash Flow to Equity (FCFE)

Amgen Inc., FCFE calculation

USD $ in millions

 
12 months ended Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
Net income
Net noncash charges
Changes in operating assets and liabilities, net of acquisitions
Net cash provided by operating activities
Purchases of property, plant and equipment
Proceeds from sale of property, plant and equipment
Net proceeds from issuance of debt
Repayment of debt
Free cash flow to equity (FCFE)
Item Description The company
FCFE Free cash flow to equity is the cash flow available to Amgen Inc.'s equity holders after all operating expenses, interest, and principal payments have been paid and necessary investments in working and fixed capital have been made. Amgen Inc.'s FCFE increased from 2015 to 2016 but then slightly declined from 2016 to 2017 not reaching 2015 level.

Top


Price to FCFE Ratio, Current

Amgen Inc., current P/FCFE calculation, comparison to benchmarks

 
No. shares of common stock outstanding
Selected Financial Data (USD $)
Free cash flow to equity (FCFE) (in millions)
FCFE per share
Current share price (P)
Ratio
P/FCFE
Benchmarks
P/FCFE, Competitors
Abbott Laboratories
AbbVie Inc.
Allergan PLC
Biogen Inc.
Bristol-Myers Squibb Co.
Celgene Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
P/FCFE, Sector
Pharmaceuticals & Biotechnology
P/FCFE, Industry
Health Care

If company P/FCFE is lower then the P/FCFE of benchmark then company is relatively undervalued.

Otherwise, if company P/FCFE is higher then the P/FCFE of benchmark then company is relatively overvalued.

Top


Price to FCFE Ratio, Historical

Amgen Inc., historical P/FCFE calculation, comparison to benchmarks

 
Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
No. shares of common stock outstanding1
Selected Financial Data (USD $)
Free cash flow to equity (FCFE) (in millions)2
FCFE per share4
Share price1, 3
Ratio
P/FCFE5
Benchmarks
P/FCFE, Competitors
Abbott Laboratories
AbbVie Inc.
Allergan PLC
Biogen Inc.
Bristol-Myers Squibb Co.
Celgene Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
P/FCFE, Sector
Pharmaceuticals & Biotechnology
P/FCFE, Industry
Health Care

1 Data adjusted for splits and stock dividends.

2 See Details »

3 Close price on the filing date of Amgen Inc.'s Annual Report.

2017 Calculations

4 FCFE per share = FCFE ÷ No. shares of common stock outstanding
= ÷ =

5 P/FCFE = Share price ÷ FCFE per share
= ÷ =

Ratio Description The company
P/FCFE Price to free cash flow to equity is cash valuation indicator of stockholders' equity. Amgen Inc.'s P/FCFE ratio declined from 2015 to 2016 but then increased from 2016 to 2017 exceeding 2015 level.

Top